DOP2005000039A - Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos - Google Patents

Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos

Info

Publication number
DOP2005000039A
DOP2005000039A DO2005000039A DO2005000039A DOP2005000039A DO P2005000039 A DOP2005000039 A DO P2005000039A DO 2005000039 A DO2005000039 A DO 2005000039A DO 2005000039 A DO2005000039 A DO 2005000039A DO P2005000039 A DOP2005000039 A DO P2005000039A
Authority
DO
Dominican Republic
Prior art keywords
compound
formula
present
inhibitor
mastocyt
Prior art date
Application number
DO2005000039A
Other languages
English (en)
Inventor
Zhongli Gao
Larry Davis
Julian Levell
Mark Czekaj
Adam W Sledeski
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of DOP2005000039A publication Critical patent/DOP2005000039A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente invención incluye el compuesto de fórmula I: O un profarmaco, sal farmacéuticamente aceptable o solvato de dicho compuesto. Ademàs, la presente invención se refiere a una composicion farmaceutica que comprende una cantidad farmacéuticamente eficaz del compuesto de fórmula I, y un vehiculo farmacéuticamente aceptable. Ademàs, la presente invención se refiere al use de un compuesto de fórmula I como un inhibidor de triptasa, que comprende introducir el compuesto en una composición que comprende triptasa. Ademàs, la presente invención se refiere al use de un compuesto de formula I para tratar a un paciente que padece o es propenso a padecer una afección fisiológica, que necesita la mejora de un inhibidor de triptasa que comprende administrar al paciente una cantidad terapéuticamente eficaz del compuesto de la reivindicación 1. La presente invención tambien se refiere a la preparacion de un compuesto de formula I.
DO2005000039A 2004-03-26 2005-03-21 Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos DOP2005000039A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55692704P 2004-03-26 2004-03-26

Publications (1)

Publication Number Publication Date
DOP2005000039A true DOP2005000039A (es) 2005-10-31

Family

ID=34964263

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2005000039A DOP2005000039A (es) 2004-03-26 2005-03-21 Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos

Country Status (25)

Country Link
US (1) US20070142435A1 (es)
EP (1) EP1737848A1 (es)
JP (1) JP2007530580A (es)
KR (1) KR20060130682A (es)
CN (1) CN1956978A (es)
AR (1) AR048336A1 (es)
AU (1) AU2005230934A1 (es)
BR (1) BRPI0509245A (es)
CA (1) CA2560649A1 (es)
CR (1) CR8603A (es)
DO (1) DOP2005000039A (es)
EC (1) ECSP066878A (es)
IL (1) IL178031A0 (es)
MA (1) MA28547B1 (es)
MX (1) MXPA06010610A (es)
NO (1) NO20064811L (es)
PA (1) PA8627601A1 (es)
PE (1) PE20060084A1 (es)
RU (1) RU2330034C1 (es)
TN (1) TNSN06278A1 (es)
TW (1) TW200602035A (es)
UA (1) UA83738C2 (es)
UY (1) UY28821A1 (es)
WO (1) WO2005097780A1 (es)
ZA (1) ZA200607752B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20071148A1 (es) * 2006-03-29 2007-12-10 Sanofi Aventis Mejoras en la preparacion de intermedios que conducen a hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona
AR065616A1 (es) * 2007-03-07 2009-06-17 Sanofi Aventis Sintesis regioselectiva de ullmann de acido 4- bromo-3- metil-5- propoxi- tiofeno-2- carboxilico
WO2008115912A1 (en) * 2007-03-21 2008-09-25 Sanofi-Aventis Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid
AR065858A1 (es) * 2007-03-29 2009-07-08 Sanofi Aventis Metodo para preparar el inhibidor de triptasa [ 4-(5-aminoetil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona.
WO2008121669A1 (en) * 2007-03-29 2008-10-09 Sanofi-Aventis 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester, its regio-specific synthesis and intermediate thereto
ES2469824T3 (es) 2007-11-21 2014-06-20 Janssen Pharmaceutica N.V. Espiropiperidinas para su uso como inhibidores de la triptasa
EP2242477B1 (en) 2008-01-24 2013-01-02 Soligenix, Inc. Topically active steroids for use in interstitial pulmonary fibrosis
MX2011001135A (es) * 2008-08-22 2011-03-21 Sanofi Aventis [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-m etoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos.
AR074776A1 (es) 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
FR2955324A1 (fr) * 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
BR112012006519A2 (pt) * 2009-09-24 2015-09-08 Sanofi Aventis Us Llc síntese de t-butil éster de ácido (4-fluór-3-piperidin-4-il-benzin)-carbâmico e seus intermediários
EP2516428A1 (en) * 2009-12-23 2012-10-31 Sanofi Tropinone benzylamines as beta-tryptase inhibitors
MX2012006805A (es) * 2009-12-23 2012-07-10 Sanofi Sa Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
MX2012006741A (es) * 2009-12-23 2012-07-04 Sanofi Sa Tratamiento para la enfermedad inflamatoria del intestino.
JP2013520506A (ja) * 2010-02-24 2013-06-06 サノフイ 皮膚科学的なアレルギー状態の治療
CA2851087C (en) 2011-10-07 2019-09-24 Takeda Pharmaceutical Company Limited 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
AR110873A1 (es) * 2017-02-10 2019-05-08 Genentech Inc Anticuerpos contra triptasa, composiciones de estos y usos de estos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012362D0 (en) * 2000-05-22 2000-07-12 Aventis Pharma Ltd Chemical compounds
HU227630B1 (hu) * 2000-05-22 2011-10-28 Aventis Pharma Inc Arilmetilamin-származékok triptáz gátlóként való alkalmazásra és ezeket tartalmazó gyógyszerkészítmények

Also Published As

Publication number Publication date
UA83738C2 (en) 2008-08-11
UY28821A1 (es) 2005-10-31
RU2006137717A (ru) 2008-05-10
PE20060084A1 (es) 2006-03-09
PA8627601A1 (es) 2006-01-23
KR20060130682A (ko) 2006-12-19
CA2560649A1 (en) 2005-10-20
ZA200607752B (en) 2008-05-28
TW200602035A (en) 2006-01-16
MA28547B1 (fr) 2007-04-03
NO20064811L (no) 2006-10-23
ECSP066878A (es) 2006-11-24
AU2005230934A1 (en) 2005-10-20
CN1956978A (zh) 2007-05-02
WO2005097780A1 (en) 2005-10-20
CR8603A (es) 2007-06-08
MXPA06010610A (es) 2006-12-15
JP2007530580A (ja) 2007-11-01
EP1737848A1 (en) 2007-01-03
TNSN06278A1 (en) 2007-12-03
BRPI0509245A (pt) 2007-09-11
AR048336A1 (es) 2006-04-19
US20070142435A1 (en) 2007-06-21
IL178031A0 (en) 2006-12-31
RU2330034C1 (ru) 2008-07-27

Similar Documents

Publication Publication Date Title
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
MY148108A (en) Medicaments for the treatment or prevention of fibrotic diseases
MX356032B (es) Compuestos indola y métodos para tratar el dolor visceral.
MY141939A (en) Pyridazine derivatives and their use as therapeutic agents
IL189546A0 (en) Therapy for the treatment of disease
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
HK1176318A1 (en) Injection device
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
TW200606164A (en) New compounds
CO6341624A2 (es) [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos
TW200800984A (en) New compounds
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
MY156278A (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
MY144229A (en) Pyridazine derivatives and their use as therapeutic agents
TNSN08093A1 (en) Quinoline derivatives and use as antitumor agents
DE602006016168D1 (de) 1,3,5-triazepin-dionen zur Behandlung von Malaria
AR062215A1 (es) Inhibidor de trombina activo por via oral
TW200744596A (en) Antitumor agents